2-(3,5-diphenyl-4-(trifluoromethyl)-1H-pyrazol-1-yl)thiazole-4-carboxylic acid

ID: ALA3092150

PubChem CID: 68329608

Max Phase: Preclinical

Molecular Formula: C20H12F3N3O2S

Molecular Weight: 415.40

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)c1csc(-n2nc(-c3ccccc3)c(C(F)(F)F)c2-c2ccccc2)n1

Standard InChI:  InChI=1S/C20H12F3N3O2S/c21-20(22,23)15-16(12-7-3-1-4-8-12)25-26(17(15)13-9-5-2-6-10-13)19-24-14(11-29-19)18(27)28/h1-11H,(H,27,28)

Standard InChI Key:  ZCBFSYOZVSEIJA-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    7.9027   -5.9833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9016   -6.8107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6163   -7.2236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3328   -6.8101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3300   -5.9797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6145   -5.5705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0424   -5.5619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7974   -5.8946    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3471   -5.2795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9320   -4.5665    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.1256   -4.7412    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.2625   -3.8131    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0688   -3.6384    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   12.1519   -2.8177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3969   -2.4849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8474   -3.1002    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.1654   -5.3636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5030   -6.1176    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3230   -6.2010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8063   -5.5312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4637   -4.7760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6448   -4.6962    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.2222   -1.6787    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8331   -1.1242    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.4366   -1.4268    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.9720   -6.7009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.7576   -6.9529    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.3609   -7.2553    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.1833   -7.4958    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  1  0
 11  7  2  0
  5  7  1  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 12  2  0
 10 12  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 17  1  0
  9 17  1  0
 15 23  1  0
 23 24  1  0
 23 25  2  0
  8 26  1  0
 26 27  1  0
 26 28  1  0
 26 29  1  0
M  END

Associated Targets(Human)

PTGER1 Tclin Prostanoid EP1 receptor (1696 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 415.40Molecular Weight (Monoisotopic): 415.0602AlogP: 5.38#Rotatable Bonds: 4
Polar Surface Area: 68.01Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.17CX Basic pKa: 0.45CX LogP: 5.92CX LogD: 2.47
Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.49Np Likeness Score: -1.16

References

1. Atobe M, Naganuma K, Kawanishi M, Morimoto A, Kasahara K, Ohashi S, Suzuki H, Hayashi T, Miyoshi S..  (2013)  SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.,  23  (24): [PMID:24252546] [10.1016/j.bmcl.2013.10.065]

Source